drugset / Trial / NCT04615962

Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.

NCT04615962

Phase 1 Unknown 66 enrolled Seanergy Dermatology Ltd.
RandomizedSingle-groupTriple-blindTreatment

Summary

The investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different strengths of topical steroids hydrocortisone and the medium potent mometasone furoate cream.

Timeline

Start
2021-01-01
Primary completion
2022-01
Completion
2022-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrocortisone Other / unclassified 1 % Topical
Comparator Mometasone Other / unclassified
Subject SNG100 Other / unclassified Topical

Indications